Case report: Bullous pemphigoid in HIV-1-positive patients: interplay or coincidence? A case series and review of the literature

Frontiers in Immunology

Immunology

Carola Berking¹  Yannick Foerster¹  Lukas Sollfrank¹  Michael Sticherling¹  Laura Rechtien¹  Thomas Harrer² 

[1] Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany;Deutsches Zentrum Immuntherapie, Erlangen, Germany;Deutsches Zentrum Immuntherapie, Erlangen, Germany;Infectious Diseases and Immunodeficiency Section, Department of Internal Medicine 3, Universitatsklinikum Erlangen, Erlangen, Germany;

关键词: bullous pemphigoid;    HIV-1;    aids;    immune reconstitution inflammatory syndrome;    iris;    dupilumab;    COVID-19;   

DOI  :  10.3389/fimmu.2023.1179294

 received in 2023-03-03, accepted in 2023-05-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Bullous pemphigoid (BP) is an autoimmune inflammatory skin disease, mostly affecting the elderly population. Therefore, patients often have multiple comorbidities, but there is inconsistent data regarding the relationship between HIV-1 infection and BP, which has been rarely reported in combination. Herein, we describe three patients who presented with BP and concomitant HIV-1 infection that was well controlled with modern combined antiretroviral therapy. All patients received topical and oral corticosteroids. Depending on the individual severity, further add-on therapeutics, such as azathioprine, dapsone, doxycycline and the interleukin 4/13 antibody dupilumab, were added to the therapy regimen. All patients recovered from pruritic skin lesions and blistering. The cases are further discussed in the context of the current study landscape. In conclusion, HIV-1 infection shifts the cytokine profile from T-helper type 1 (TH1) towards T-helper type 2 (TH2), resulting in the excessive secretion of distinct cytokines, such as interleukin 4 (IL-4) and interleukin 10 (IL-10). With IL-4 being a main driver in the pathogenesis of BP, HIV-1-positive patients may benefit greatly from targeting IL-4 with monoclonal antibodies.

【 授权许可】

Unknown   
Copyright © 2023 Foerster, Sollfrank, Rechtien, Harrer, Berking and Sticherling